NASDAQ: RARE

Ultragenyx Pharmaceutical Inc Stock Forecast, Predictions & Price Target

The consensus among 11 Wall Street analysts covering (NASDAQ: RARE) stock is to Strong Buy RARE stock.

Out of 11 analysts, 8 (72.73%) are recommending RARE as a Strong Buy, 2 (18.18%) are recommending RARE as a Buy, 1 (9.09%) are recommending RARE as a Hold, 0 (0%) are recommending RARE as a Sell, and 0 (0%) are recommending RARE as a Strong Sell.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 23.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Ultragenyx Pharmaceutical's revenue in 2024 is $442,586,000.On average, 9 Wall Street analysts forecast RARE's revenue for 2024 to be $42,616,810,864, with the lowest RARE revenue forecast at $41,691,370,512, and the highest RARE revenue forecast at $43,665,787,360. On average, 9 Wall Street analysts forecast RARE's revenue for 2025 to be $51,092,836,912, with the lowest RARE revenue forecast at $46,471,537,619, and the highest RARE revenue forecast at $58,965,647,438.

In 2026, RARE is forecast to generate $71,328,905,378 in revenue, with the lowest revenue forecast at $56,788,385,237 and the highest revenue forecast at $86,693,941,995.

According to 11 Wall Street analysts that have issued a 1 year RARE price target, the average RARE price target is $85.36, with the highest RARE stock price forecast at $127.00 and the lowest RARE stock price forecast at $48.00.

On average, Wall Street analysts predict that Ultragenyx Pharmaceutical's share price could reach $85.36 by May 31, 2025. The average Ultragenyx Pharmaceutical stock price prediction forecasts a potential upside of 112.67% from the current RARE share price of $40.14.

(NASDAQ: RARE) forecast ROE is N/A, which is considered weak.